# Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis

> **NCT02019758** · PHASE4 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 129 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Oral Viscous Budesonide
- **DRUG:** Fluticasone MDI
- **DRUG:** Placebo slurry
- **DRUG:** Placebo inhaler

## Key facts

- **NCT ID:** NCT02019758
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2018-05
- **Final completion:** 2019-04
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2020-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019758, "Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02019758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*